Premium
Assessement of the pharmacokinetics, tissue distribution and excretion studies of a novel antiplatelet agent S007‐867, following administration to rats
Author(s) -
Chandasana Hardik,
Chhonker Yashpal S.,
Laxman Tulsankar Sachin,
Prasad Yarra Durga,
K. S. Anil Kumar,
Dikshit Dinesh K.,
Bhatta Rabi S.
Publication year - 2016
Publication title -
drug testing and analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 54
eISSN - 1942-7611
pISSN - 1942-7603
DOI - 10.1002/dta.1811
Subject(s) - pharmacokinetics , pharmacology , urine , chemistry , bioanalysis , distribution (mathematics) , metabolite , absorption (acoustics) , kidney , drug , excretion , oral administration , spleen , medicine , chromatography , biochemistry , mathematical analysis , physics , mathematics , acoustics
S007‐867 is a promising novel antiplatelet agent with better efficacy and lesser bleeding risk than existing agents. The present study investigated the absorption, tissue distribution, and excretion of S007‐867 in rat model for further advancement of the molecule. A simple and robust ultra fast liquid chromatography‐tandem mass spectrometry (UFLC‐MS/MS) bioanalytical method was used to determine S007‐867 in various matrices. Following oral administration, the compound was quickly dispersed in the various tissues and peak concentration levels were achieved within 0.5–1 h. Overall, exposure of drug, i.e., AUC in different tissues was found in the order of small intestine > liver > heart > spleen > lungs > kidney > brain. The total recoveries of the S007‐867 within 96 h were 3.36% in urine and faeces. This might be due to a first‐pass effect by the liver and intestine as most of the drug was eliminated in metabolite form. These findings provide a crucial information about further development of S007‐867 as antithrombotic agent. Copyright © 2015 John Wiley & Sons, Ltd.